(Q34416807)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

chronic myeloid leukemia

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

2

Hana Klamová

1 reference

19 January 2020

Zuzana Humlová

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ivana Janatková

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Petra Králíková

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ivan Sterzl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Zdeněk Roth

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Eva Hamšíková

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Vladimír Vonka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

12 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Developmental Immunology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

137320

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

19 January 2020

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Immunotherapy of chronic myeloid leukemia: present state and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Dynamics and potential impact of the immune response to chronic myelogenous leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Defective T cell development and function in the absence of Abelson kinases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

C-reactive protein (CRP) and autoimmune disease: facts and conjectures.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Overriding imatinib resistance with a novel ABL kinase inhibitor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Hydroxyurea-induced dermatomyositis-like eruption

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

The molecular biology of chronic myeloid leukemia.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

6 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Selective effect of imatinib on serum IgM in a patient with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F137320

Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3004381

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

27 October 2018

1 reference

12 December 2020

Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia

1 reference

12 December 2020

Serial complement measurements in patients with leukaemia

1 reference

12 December 2020

Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia

1 reference

12 December 2020

Chronic myelogenous leukaemia: haematological remissions with alpha interferon

1 reference

12 December 2020

Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha

1 reference

12 December 2020

Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia

1 reference

12 December 2020

Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro

1 reference

12 December 2020

IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2.

1 reference

12 December 2020

Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer

1 reference

12 December 2020

Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis

1 reference

12 December 2020

Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/137320

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21197073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference